Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Worldwide Resipiratory Drugs Market 2016 Analysis and Forecast 2020

Thursday, September 22, 2016 6:10
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Asthma, COPD, allergic rhinitis, pulmonary hypertension, cystic fibrosis, and IPF are some of the major respiratory diseases. Among these, asthma and COPD are the most prevalent worldwide. Environmental pollution, changing lifestyles, and hereditary factors are some of the common causes of respiratory diseases. Intranasal corticosteroids, antihistamines, immunosuppressants, bronchodilators, and leukotriene antagonists are the respiratory medicines that are commonly used for the treatment of mild-to-moderate respiratory diseases. However, the choice of drug depends on the type and severity of the disease.

Publisher’s analysts forecast the global respiratory drugs market to grow at a CAGR of 6.48% during the period 2016-2020.

For more information about this report: http://www.reportsweb.com/global-resipiratory-drugs-market-2016-2020 .

The report covers the present scenario and the growth prospects of the global respiratory drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription and over-the-counter (OTC) drugs used to treat respiratory diseases.

The market is divided into the following segments based on geography: 
- Americas
- APAC
- EMEA

Publisher’s report, Global Respiratory Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

 

Make an enquiry: http://www.reportsweb.com/inquiry&RW0001236122/buying .

 

Key vendors 
- AstraZeneca
- Boehringer Ingelheim
- F.Hoffman La-Roche
- GlaxoSmithKline
- Merck
- Novartis

Other prominent vendors 
- Abbott
- Actavis
- Afferent Pharmaceuticals
- Alere
- Almirall
- Amgen
- AptarGroup
- Astellas
- Aurobindo
- Axis Shield
- Baxter
- Bayer
- Biogen
- Biotest
- Bristol-Myers Squibb
- Chiesi Farmaceutici
- Cipla
- Cytos
- Dainippon Sumitomo
- Dr. Reddy’s Laboratories
- FibroGen
- Gilead Sciences
- Glenmark
- GNI Group Ltd
- Horizon Pharma
- ImmuneWorks
- MediciNova
- MedImmune
- Mylan
- Ono Pharmaceutical
- Orchid Chemicals and Pharmaceuticals
- Perrigo
- Pfizer
- Promedior
- Prometheus
- ProMetic Life Sciences
- Ranbaxy
- Rottapharm Madaus
- Sanofi
- Shionogi
- Siemens Healthcare Diagnostics
- Skyepharma
- Sosei
Sunovion
- Takeda Pharmaceutical 
- Teva
- Theravance
- United Therapeutics
- Vectura
- Vertex
- Zai Lab

Market driver 
- Rise in prevalence of respiratory diseases
- For a full, detailed list, view our report 

Market challenge 
- Unknown etiology of asthma and idiopathic pulmonary fibrosis
- For a full, detailed list, view our report 

Market trend 
- Use of biologics
- For a full, detailed list, view our report 

 

Buy this Report: http://www.reportsweb.com/buy&RW0001236122/buy/2500 .

Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.